Sharps Technology signs $200M syringe sales agreement with Nephron Pharmaceuticals

Sharps Technology Inc. signed a 5-year, $200 million syringe sales agreement with Nephron Pharmaceuticals, complementing its asset purchase agreement to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. Product delivery is scheduled to begin in Q2 2025.

“Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S.”biospace.com

• 1 source
• biospace.comSharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S. - BioSpaceAnnalee ArmstrongMay 30, 2024

Summarized from public sources; check the original articles before acting on it.